Russell Investments Group
MRSN

Russell Investments Group’s Mersana Therapeutics MRSN Stock Holding History

Russell Investments Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-472
Closed -$16.9K – 3849
2024
Q4 		$16.9K Buy
472
+41
+10% +$2.12K ﹤0.01% 3043
2024
Q3 		$20.3K Buy
431
+50
+13% +$2.21K ﹤0.01% 2953
2024
Q2 		$19.1K Buy
381
+3
+0.8% +$217 ﹤0.01% 2945
2024
Q1 		$42.4K Buy
378
+343
+980% +$34.1K ﹤0.01% 2687
2023
Q4 		$2.04K Hold
35
– – ﹤0.01% 3009
2023
Q3 		$1.11K Sell
35
-3,956
-99% -$188K ﹤0.01% 3333
2023
Q2 		$328K Buy
3,991
+3,255
+442% +$476K ﹤0.01% 2351
2023
Q1 		$75.6K Sell
736
-200
-21% -$28.1K ﹤0.01% 2642
2022
Q4 		$137K Buy
936
+80
+9% +$13.5K ﹤0.01% 2620
2022
Q3 		$144K Buy
856
+677
+378% +$110K ﹤0.01% 2613
2022
Q2 		$20K Sell
179
-2,079
-92% -$196K ﹤0.01% 2799
2022
Q1 		$224K Buy
+2,258
New +$264K ﹤0.01% 2437
2021
Q1 		– Sell
-268
Closed -$177K – 3167
2020
Q4 		$177K Sell
268
-431
-62% -$240K ﹤0.01% 2785
2020
Q3 		$325K Sell
699
-1,369
-66% -$692K ﹤0.01% 2580
2020
Q2 		$1.2M Sell
2,068
-1,621
-44% -$554K ﹤0.01% 1945
2020
Q1 		$541K Buy
+3,689
New +$645K ﹤0.01% 2139
2019
Q4 		– Sell
-723
Closed -$28K – 3111
2019
Q3 		$28K Buy
723
+167
+30% +$12.1K ﹤0.01% 2958
2019
Q2 		$56K Buy
556
+164
+42% +$19.3K ﹤0.01% 2718
2019
Q1 		$51K Buy
+392
New +$49.3K ﹤0.01% 2799
2018
Q3 		– Sell
-1,714
Closed -$766K – 2994
2018
Q2 		$766K Hold
1,714
– – ﹤0.01% 2255
2018
Q1 		$676K Buy
+1,714
New +$677K ﹤0.01% 2365

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Russell Investments Group's MRSN Position: Q1 2025 in Review

Russell Investments Group sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 472 shares — an estimated $16.9K sold.

Russell Investments Group first reported a position in MRSN in Q1 2018 and held it in 21 quarters. The position peaked at $1.2M in Q2 2020. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Russell Investments Group reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Russell Investments Group sold 472 Mersana Therapeutics shares in Q1 2025, an estimated $16.9K.
  • Russell Investments Group first reported a position in Mersana Therapeutics in Q1 2018 and held it in 21 quarters.
  • Russell Investments Group's Mersana Therapeutics position peaked at $1.2M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Russell Investments Group's 13F filing for Q1 2025, filed 13 May 2025.